Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? (Q35162483)

6 August 2017

1 reference

title

Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? (English)

1 reference

pancreatic adenocarcinoma

6 August 2017

1 reference

1 reference

Ross A Abrams

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

International Journal of Radiation Oncology Biology Physics

6 August 2017

published in

1 reference

6 August 2017

volume

56

1 reference

6 August 2017

issue

4 Suppl

1 reference

6 August 2017

page(s)

3-9

1 reference

6 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Combined postoperative radiotherapy and Weekly Cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Prolongation of the disease-free interval in surgically treated rectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Patterns of failure after curative resection of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973—Analysis of surgical failure and implications for radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Complex gastrointestinal surgery: impact of provider experience on clinical and economic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Hospital volume and surgical mortality in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Resection for adenocarcinoma of the body and tail of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Adjuvant therapy for pancreatic cancer: back to the future

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Continuing controversy over adjuvant therapy of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900451-6

7 January 2021

10.1016/S0360-3016(03)00451-6

Identifiers

DOI

1 reference

6 August 2017

1 reference